Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma
LTS and STS show distinct clinical and molecular features, underscoring the importance of extended molecular workup for diagnosis. Further characterization of rare subtypes is needed to optimize treatment strategies and clinical trial planning.
Authors
- Lisa Müller (ORCID: https://orcid.org/0000-0002-0728-0012)
- Anna Sophie Berghoff (ORCID: https://orcid.org/0000-0001-9379-6797)
- Serge Weis (ORCID: https://orcid.org/0000-0001-6750-2599)
- Franziska Eckert (ORCID: https://orcid.org/0000-0002-4742-3962)
- Barbara Kiesel (ORCID: https://orcid.org/0000-0003-0939-9831)
- Gerwin Heller (ORCID: https://orcid.org/0000-0001-8742-5631)
- Annette Leibetseder (ORCID: https://orcid.org/0000-0002-5254-8743)
- Josef Pichler (ORCID: https://orcid.org/0000-0001-9611-7075)
- Matthias Preusser (ORCID: https://orcid.org/0000-0003-3541-2315)
- Georg Widhalm (ORCID: https://orcid.org/0000-0001-6014-0273)
- Inga Busse
- Maximilian J. Mair (ORCID: https://orcid.org/0000-0002-6537-3874)
- Erwin Tomasich (ORCID: https://orcid.org/0000-0002-7069-2247)
- Adelheid Wöhrer
Institutions
- Kepler Universitätsklinikum (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1007/s00415-025-12923-6
- Citations
- 3
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.88
Funders
- European Association of Neuro-Oncology
- Kepler Universitätsklinikum
- Medizinische Universität Wien
- European Society for Medical Oncology